Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Thrombosis: a major contributor to global disease burden.Arterioscler Thromb Vasc Biol. 2014; 34: 2363-2371https://doi.org/10.1161/ATVBAHA.114.304488
- The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients.Haematologica. 2007; 92: 199-205
- Recent advances in the treatment of venous thromboembolism in the era of the direct oral anticoagulants.F1000Res . 2017; 6: 985https://doi.org/10.12688/f1000research.11174.1
- Systematic review of prognostic models for recurrent venous thromboembolism (VTE) post-treatment of first unprovoked VTE.BMJ Open. 2016; 6e011190https://doi.org/10.1136/bmjopen-2016-011190
- Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Chest. 2012; 141: e195S-226https://doi.org/10.1378/chest.11-2296
Mazzolai L, Aboyans V, Ageno W, et al. Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European society of cardiology working groups of aorta and peripheral circulation and pulmonary circulation and right ventricular function [e-pub ahead of print]. Eur Heart J. doi:10.1093/eurheartj/ehx003, Accessed July 7, 2018.
- The Danish Civil Registration System as a tool in epidemiology.Eur J Epidemiol. 2014; 29: 541-549https://doi.org/10.1007/s10654-014-9930-3
- The Danish National Patient Register.Scand J Public Health. 2011; 39: 30-33https://doi.org/10.1177/1403494811401482
- The Danish National Prescription Registry.Scand J Public Health. 2011; 39: 38-41https://doi.org/10.1177/1403494810394717
- Venous thromboembolism discharge diagnoses in the Danish National Patient Registry should be used with caution.J Clin Epidemiol. 2010; 63: 223-228https://doi.org/10.1016/j.jclinepi.2009.03.018
- Approach to thrombosis at unusual sites: splanchnic and cerebral vein thrombosis.Vasc Med. 2017; 22: 529-540https://doi.org/10.1177/1358863X17734057
- Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report.Chest. 2016; 149: 315-352https://doi.org/10.1016/j.chest.2015.11.026
- 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism.Eur Heart J. 2014; 35: 3033-3080https://doi.org/10.1093/eurheartj/ehu283
- Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH.J Thromb Haemost. 2016; 14: 1480-1483https://doi.org/10.1111/jth.13336
- Risk factors for venous thromboembolism.J Am Coll Cardiol. 2010; 56: 1-7https://doi.org/10.1016/j.jacc.2010.01.057
- A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis.Am J Cardiol. 2004; 93: 259-262https://doi.org/10.1016/j.amjcard.2003.09.057
- Positive predictive value of cardiovascular diagnoses in the Danish National Patient Registry: a validation study.BMJ Open. 2016; 6e012832https://doi.org/10.1136/bmjopen-2016-012832
- Venous thromboembolism management practices and knowledge of guidelines: a survey of Australian haematologists and respiratory physicians.Intern Med J. 2017; 47: 436-446https://doi.org/10.1111/imj.13382
- Imaging trends in acute venous thromboembolic disease: 2000 to 2015.J Am Coll Radiol. 2017; 14: 1151-1160https://doi.org/10.1016/j.jacr.2017.05.012
- Introduction to the analysis of survival data in the presence of competing risks.Circulation. 2016; 133: 601-609https://doi.org/10.1161/CIRCULATIONAHA.115.017719
- Epidemiology of first and recurrent venous thromboembolism: a population-based cohort study in patients without active cancer.Thromb Haemost. 2014; 112: 255-263https://doi.org/10.1160/TH13-09-0793
- Recurrence and mortality after first venous thromboembolism in a large population-based cohort.J Thromb Haemost. 2016; 38: 42-49https://doi.org/10.1111/jth.13587
- Retrospective evaluation of venous thromboembolism: are all transient provoking events the same?.Eur J Haematol. 2017; 99: 18-26https://doi.org/10.1111/ejh.12884
- The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly.Arch Intern Med. 1994; 154: 861-866
- A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism.N Engl J Med. 1995; 332: 1661-1665https://doi.org/10.1056/NEJM199506223322501
- Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study.Lancet. 2003; 362: 523-526https://doi.org/10.1016/S0140-6736(03)14111-6
- Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism.Ann Intern Med. 2010; 152: 578-589https://doi.org/10.7326/0003-4819-152-9-201005040-00008
☆Funding: The Obel Family Foundation partly funded this research by an unrestricted grant. The sponsor had no role in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; the writing of the report; or the decision to submit the paper for publication.
✯✯Conflict of Interest: TBL has served as an investigator for Janssen Scientific Affairs LLC and Boehringer Ingelheim, and has been on the speaker bureaus for Bayer, BMS/Pfizer, Roche Diagnostics, Boehringer Ingelheim, and Takeda Pharma. PBN has received speaking fees from Boehringer Ingelheim, BMS/Pfizer, and Bayer AG; consulting fees from Bayer; and grant support from BMF/Pfizer. SZG receives honoraria for consulting activities from Bayer, Boehringer Ingelheim, BMS, Daiichi Sankyo, Janssen, Portola, Agile, eXlthera, and Soleno, and receives research support from BiO2 Medical; Boehringer Ingelheim; BMS; BTG EKOS; Daiichi; the National Heart, Lung, and Blood Institute of the National Institutes of Health; Janssen; and the Thrombosis Research Institute. All other authors have no disclosures to report.
✯Authorship: All authors had access to the data and a role in writing this manuscript.